CHICAGO (GenomeWeb) – Sophia Genetics said that it has received a CE-IVD mark for a molecular diagnostics test designed to improve detection of leukemia and other hematological diseases. The Swiss company called this the "world’s first capture-based myeloid clinical solution" to receive this designation from European regulators.

The test is a sequencing-based assay combined with data analytics to detect mutations that cause myeloid and lymphoid leukemia.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.